Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Biomarker, By Cancer Sub-Type, By Offering, By End User, By Region & Competition, 2021-2031F

Description

The Global Next-Generation Breast Cancer Diagnostic and Screening Market is poised for substantial growth, projected to increase from USD 4.81 Billion in 2025 to USD 8.84 Billion by 2031, at a CAGR of 10.68%. This market includes advanced solutions like genomic profiling assays, liquid biopsy platforms, and AI-enhanced imaging systems, all designed to offer superior precision in detecting malignancies compared to traditional methods. Market expansion is primarily fueled by the rising global prevalence of breast cancer and a significant shift towards personalized medicine, which demands molecular-level tumor analysis for effective treatment strategies. For instance, the American Cancer Society anticipated approximately 316,950 women in the United States would be diagnosed with invasive breast cancer in 2025, highlighting the critical demand for these precise diagnostic capabilities.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 4.81 Billion
Market Size 2031	USD 8.84 Billion
CAGR 2026-2031	10.68%
Fastest Growing Segment	Products
Largest Market	North America

Market Driver

A primary market driver is the integration of Artificial Intelligence (AI) in diagnostic imaging, which fundamentally enhances screening protocols by improving sensitivity and optimizing radiologist workflows. AI algorithms effectively identify subtle malignancies and mitigate false negatives in dense breast tissue, thereby significantly boosting diagnostic accuracy; a real-world study showed AI-supported screening increased breast cancer detection rates by 17.6%, achieving 6.7 detections per 1,000 women. Simultaneously, the increasing adoption of liquid biopsy and non-invasive diagnostics is transforming personalized medicine and treatment monitoring. These genomic tools enable early detection of circulating tumor DNA, allowing clinicians to dynamically tailor therapies and detect recurrence sooner than traditional imaging, proving vital as global breast cancer cases are projected to rise to 3.2 million annually by 2050.

Market Challenge

The high implementation costs associated with advanced technologies represent a significant challenge to the growth of the Global Next-Generation Breast Cancer Diagnostic and Screening Market. Integrating genomic profiling assays and AI-driven imaging systems demands substantial capital investment and specialized infrastructure, creating a financial barrier that many healthcare facilities, particularly in price-sensitive regions with stretched budgets, find difficult to overcome. Furthermore, existing reimbursement frameworks often inadequately cover the premium pricing of these innovative solutions, compelling providers to opt for less expensive, traditional methods despite the potential for enhanced detection. This economic strain extends to national health systems, where the substantial financial burden of breast cancer, projected to cost the UK economy between £3.2 billion and £3.5 billion annually in 2025, often prioritizes strict cost-containment measures over the adoption of premium diagnostic technologies, consequently limiting market scaling and widespread implementation.

Market Trends

The implementation of Automated Breast Ultrasound (ABUS) for screening dense breast tissue is becoming a key diagnostic standard, effectively addressing the limitations of conventional mammography, which often struggles with such tissue density. This volumetric 3D ultrasound technology ensures consistent, reproducible screening by de-linking image acquisition from operator skill, crucial for reducing false negatives and detecting interval cancers missed by X-ray systems; the Invenia ABUS Premium system, for example, detected 35.7% more cancers when used with mammography. Concurrently, the rising utilization of Contrast-Enhanced Mammography (CEM) offers a highly sensitive and cost-effective alternative to Magnetic Resonance Imaging (MRI) for high-risk assessments and inconclusive diagnoses. CEM utilizes iodinated contrast agents to visualize tumor neovascularization, providing superior clarity for lesion detection without the considerable operational costs or accessibility constraints of MRI protocols, with clinical studies indicating it successfully depicted 90% of breast cancers compared to just 10% with low-energy mammograms.

Key Market Players

Exact Sciences Corporation
F. Hoffmann-La Roche Ltd.
Abbott Laboratories, Inc.
Thermo Fisher Scientific Inc.
Hologic, Inc.
Siemens Healthineers AG
Danaher Corporation
Becton, Dickinson and Company
Agilent Technologies, Inc.
Sysmex Corporation

Report Scope

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology

Real-Time PCR
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescence In-Situ Hybridization (FISH)
Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker

BRCA1/2
ER/PR Receptors
HER-2
Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type

Luminal A
Luminal B
Triple Negative/Basal Like
Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering

Products
Services

Next-Generation Breast Cancer Diagnostic and Screening Market, By End User

Hospitals and Clinics
Diagnostic Centers and Reference Labs
Academic & Research Institutes

Next-Generation Breast Cancer Diagnostic and Screening Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
- 5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
- 5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
- 5.2.4. By Offering (Products, Services)
- 5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic & Research Institutes)
- 5.2.6. By Region
- 5.2.7. By Company (2025)
5.3. Market Map

6. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Technology
- 6.2.2. By Biomarker
- 6.2.3. By Cancer Sub-Type
- 6.2.4. By Offering
- 6.2.5. By End User
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Technology
    - 6.3.1.2.2. By Biomarker
    - 6.3.1.2.3. By Cancer Sub-Type
    - 6.3.1.2.4. By Offering
    - 6.3.1.2.5. By End User
- 6.3.2. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Technology
    - 6.3.2.2.2. By Biomarker
    - 6.3.2.2.3. By Cancer Sub-Type
    - 6.3.2.2.4. By Offering
    - 6.3.2.2.5. By End User
- 6.3.3. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Technology
    - 6.3.3.2.2. By Biomarker
    - 6.3.3.2.3. By Cancer Sub-Type
    - 6.3.3.2.4. By Offering
    - 6.3.3.2.5. By End User

7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Biomarker
- 7.2.3. By Cancer Sub-Type
- 7.2.4. By Offering
- 7.2.5. By End User
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Technology
    - 7.3.1.2.2. By Biomarker
    - 7.3.1.2.3. By Cancer Sub-Type
    - 7.3.1.2.4. By Offering
    - 7.3.1.2.5. By End User
- 7.3.2. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Technology
    - 7.3.2.2.2. By Biomarker
    - 7.3.2.2.3. By Cancer Sub-Type
    - 7.3.2.2.4. By Offering
    - 7.3.2.2.5. By End User
- 7.3.3. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Technology
    - 7.3.3.2.2. By Biomarker
    - 7.3.3.2.3. By Cancer Sub-Type
    - 7.3.3.2.4. By Offering
    - 7.3.3.2.5. By End User
- 7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Technology
    - 7.3.4.2.2. By Biomarker
    - 7.3.4.2.3. By Cancer Sub-Type
    - 7.3.4.2.4. By Offering
    - 7.3.4.2.5. By End User
- 7.3.5. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Technology
    - 7.3.5.2.2. By Biomarker
    - 7.3.5.2.3. By Cancer Sub-Type
    - 7.3.5.2.4. By Offering
    - 7.3.5.2.5. By End User

8. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Biomarker
- 8.2.3. By Cancer Sub-Type
- 8.2.4. By Offering
- 8.2.5. By End User
- 8.2.6. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Technology
    - 8.3.1.2.2. By Biomarker
    - 8.3.1.2.3. By Cancer Sub-Type
    - 8.3.1.2.4. By Offering
    - 8.3.1.2.5. By End User
- 8.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Technology
    - 8.3.2.2.2. By Biomarker
    - 8.3.2.2.3. By Cancer Sub-Type
    - 8.3.2.2.4. By Offering
    - 8.3.2.2.5. By End User
- 8.3.3. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Technology
    - 8.3.3.2.2. By Biomarker
    - 8.3.3.2.3. By Cancer Sub-Type
    - 8.3.3.2.4. By Offering
    - 8.3.3.2.5. By End User
- 8.3.4. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Technology
    - 8.3.4.2.2. By Biomarker
    - 8.3.4.2.3. By Cancer Sub-Type
    - 8.3.4.2.4. By Offering
    - 8.3.4.2.5. By End User
- 8.3.5. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Technology
    - 8.3.5.2.2. By Biomarker
    - 8.3.5.2.3. By Cancer Sub-Type
    - 8.3.5.2.4. By Offering
    - 8.3.5.2.5. By End User

9. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Biomarker
- 9.2.3. By Cancer Sub-Type
- 9.2.4. By Offering
- 9.2.5. By End User
- 9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Technology
    - 9.3.1.2.2. By Biomarker
    - 9.3.1.2.3. By Cancer Sub-Type
    - 9.3.1.2.4. By Offering
    - 9.3.1.2.5. By End User
- 9.3.2. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Technology
    - 9.3.2.2.2. By Biomarker
    - 9.3.2.2.3. By Cancer Sub-Type
    - 9.3.2.2.4. By Offering
    - 9.3.2.2.5. By End User
- 9.3.3. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Technology
    - 9.3.3.2.2. By Biomarker
    - 9.3.3.2.3. By Cancer Sub-Type
    - 9.3.3.2.4. By Offering
    - 9.3.3.2.5. By End User

10. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Biomarker
- 10.2.3. By Cancer Sub-Type
- 10.2.4. By Offering
- 10.2.5. By End User
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Technology
    - 10.3.1.2.2. By Biomarker
    - 10.3.1.2.3. By Cancer Sub-Type
    - 10.3.1.2.4. By Offering
    - 10.3.1.2.5. By End User
- 10.3.2. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Technology
    - 10.3.2.2.2. By Biomarker
    - 10.3.2.2.3. By Cancer Sub-Type
    - 10.3.2.2.4. By Offering
    - 10.3.2.2.5. By End User
- 10.3.3. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Technology
    - 10.3.3.2.2. By Biomarker
    - 10.3.3.2.3. By Cancer Sub-Type
    - 10.3.3.2.4. By Offering
    - 10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Exact Sciences Corporation
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Abbott Laboratories, Inc.
15.4. Thermo Fisher Scientific Inc.
15.5. Hologic, Inc.
15.6. Siemens Healthineers AG
15.7. Danaher Corporation
15.8. Becton, Dickinson and Company
15.9. Agilent Technologies, Inc.
15.10. Sysmex Corporation